Maternal pravastatin therapy prevents the fetal programming of adverse metabolic outcomes associated with preeclampsia in the offspring.
Postpartum contraceptive use, including use of more effective methods, was highest when contraceptive counseling was provided during both prenatal and postpartum time periods.
This prospective study demonstrates that noninvasive prenatal analysis of cfDNA from maternal plasma is an accurate advanced screening test for trisomies 21, 18 and 13.
Maternal mortality may be reduced with the use of disease-specific protocols. Most maternal deaths are not predictable at the time of admission.
The Maternal Health Clinic targets patients with increased risk of cardiovascular disease following a pregnancy-related complication in order to provide postpartum cardiovascular risk assessment and follow-up.
High-risk human papillomavirus at entry to prenatal care is associated with increased risk of preeclampsia.